Pravastatin vs Atorvastatin: PROVE IT TIMI 22 Study

Cannon CP et al conducted a clinical study (PROVE IT TIMI 22)  to assess the benefits of intensive statin therapy vs. moderate statin therapy in preventing death from any cause or major cardiovascular events in patients with acute coronary syndrome (ACS). The objective is to establish the noninferiority of pravastatin vs atorvastatin. 

Study Summary

---

About the Author

Mrs. Purnima Reddy Katkuri is a scientific writer with 4+ years of experience in content development and medical communications. Her passion for precision and attention to detail made her a reliable writer known for delivering high-quality scientific content to pharma clients. She has proven skills in editing and proofreading scientific documents while conforming to medical style guide. Her drafts are clear, correct, concise, and creative. 

---

Abbreviations

UA: Unstable Angina; ACS: Acute Coronary Syndrome; MI: Myocardial Infarction; 

---

Reference

1. Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495-504.

---

Disclaimer

The matter published on this platform has been developed by independent medical writers from various healthcare backgrounds including members of MedWriters Alumni Network. Although great care has been taken in compiling and checking the information, the authors, Rxnews team and its partners or agents, and sponsors shall not be responsible or in any way liable for any errors, omissions, or inaccuracies in this blog article whether arising from negligence or otherwise, however or for any consequences arising therefrom. The inclusion and exclusion of any product do not mention that the publisher advocates or rejects its use generally or in any particular field or field. For any complaints or feedback please write to content@rxnews.in